Takeda Pharmaceutical Company Limited Increase Through New Leases Liabilities Arising From Financing Activities
Takeda Pharmaceutical Company Limited (TAK) reported Increase Through New Leases Liabilities Arising From Financing Activities of JPY 7.75 billion for the 12-month period ending 2025-03-31, per its 20-F filed 2025-06-25.
Financial Statements › Cash Flow › Financing Activities
ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities · last filed 2025-06-25
| Period end | Increase Through New Leases Liabilities Arising From Financing Activities 12 month |
|---|---|
| 2025-03-31 | 7.75B JPY 20-F · filed 2025-06-25 |
| 2024-03-31 | 136.71B JPY 20-F · filed 2025-06-25 |
| 2023-03-31 | 25.34B JPY 20-F · filed 2024-06-26 |
| 2022-03-31 | 33.82B JPY 20-F · filed 2023-06-28 |
| 2021-03-31 | 99.68B JPY 20-F · filed 2022-06-29 |
| 2020-03-31 | 18.38B JPY 20-F · filed 2020-06-24 |
| 2019-03-31 | 118.04B JPY 20-F · filed 2020-06-24 |
| 2018-03-31 | 375.00M JPY 20-F · filed 2019-06-27 |